An award-winning journalist and New York Times best-selling author, David Faber is a co-anchor of CNBC's "Squawk on the Street" (M-F: 9 a.m.-12 p.m. ET) and an anchor and co-producer of CNBC's acclaimed original documentaries and long-form programming.
During the day, Faber breaks news and provides in-depth analysis on a range of business topics during the "Faber Report." In his 20 years with CNBC, Faber has broken many big financial stories including the massive fraud at WorldCom, the bailout of the hedge fund Long Term Capital Management and Rupert Murdoch's unsolicited bid for Dow Jones.
Faber has reported nine documentaries for CNBC for which he has received Loeb, Emmy, Peabody and duPont awards.
His book, "The Faber Report," was published by Little, Brown in spring 2002; his second book, "And Then the Roof Caved In," was published in the summer of 2009 by John Wiley.
He holds a bachelor's degree in English from Tufts University.
Follow David Faber on Twitter
The very large French pharmaceutical company made an informal acquisition approach to Genzyme. That approach was essentially rebuffed and not met with any significant talks, according to people familiar with the matter. However, especially in recent days, talks have been heating up.
Participants in that auction tell me, in recent days, it has slowed and while there was significant interest from PE initially, that interest is now being described as more modest, though bankers tell me a few sponsors continue to work on a deal.
It remains unclear how the assets on European banks’ balance sheets will be marked down under various stresses. So, will there be a need for significant capital at European banks and if the stress tests are deemed worthy, will that allow those banks to raise the necessary capital?
When Argon ST, a defense contractor, was first for sale there was ample time for plenty of takeover stock investors to get involved on hopes that a knock-out bid would emerge for the company. Sure enough, it did.